Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Keisuke Okamoto, Yoshitaka Saito, Hinata Ueda, Katsuya Narumi, Ayako Furugen, Masaki Kobayashi
{"title":"Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells","authors":"Keisuke Okamoto,&nbsp;Yoshitaka Saito,&nbsp;Hinata Ueda,&nbsp;Katsuya Narumi,&nbsp;Ayako Furugen,&nbsp;Masaki Kobayashi","doi":"10.1002/bdd.2298","DOIUrl":null,"url":null,"abstract":"<p>Cystine/glutamate transporter (xCT) is an antiporter involved in cystine uptake and glutamate efflux. However, there are very few reports regarding the kinetic analysis of xCT for cystine uptake using cancer cell lines, as well as the inhibition pattern of sulfasalazine, an inhibitor of xCT, for cystine uptake. Therefore, the purpose of this study was to clarify the kinetics of xCT in A549 cells, human lung cancer cells, and to reveal the inhibition pattern of sulfasalazine. Cystine uptake occurred in a time-dependent manner, with linear cystine uptake observed for 5 min. Additionally, sulfasalazine inhibited cystine uptake in a concentration-dependent manner, presenting an IC<sub>50</sub> value of 24.7 ± 5.6 μM. Cystine uptake was saturated with increasing concentration, demonstrating <i>K</i><sub>m</sub> and <i>V</i><sub>max</sub> values of 179.4 ± 26.7 μM and 30.4 ± 2.3 nmol/min/mg protein, respectively. Moreover, during cystine uptake with sulfasalazine, <i>K</i><sub>m</sub> and <i>V</i><sub>max</sub> were &gt;300 μM and 8.0 ± 1.5 nmol/min/mg protein, respectively, suggesting that sulfasalazine might demonstrate a mixed inhibition pattern. Furthermore, xCT siRNA decreased the xCT mRNA level and reduced cystine uptake. In conclusion, xCT was involved in the cystine uptake in A549 cells and sulfasalazine showed a mixed inhibition pattern to xCT.</p>","PeriodicalId":8865,"journal":{"name":"Biopharmaceutics & Drug Disposition","volume":"42 8","pages":"389-392"},"PeriodicalIF":1.7000,"publicationDate":"2021-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/bdd.2298","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biopharmaceutics & Drug Disposition","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bdd.2298","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

Cystine/glutamate transporter (xCT) is an antiporter involved in cystine uptake and glutamate efflux. However, there are very few reports regarding the kinetic analysis of xCT for cystine uptake using cancer cell lines, as well as the inhibition pattern of sulfasalazine, an inhibitor of xCT, for cystine uptake. Therefore, the purpose of this study was to clarify the kinetics of xCT in A549 cells, human lung cancer cells, and to reveal the inhibition pattern of sulfasalazine. Cystine uptake occurred in a time-dependent manner, with linear cystine uptake observed for 5 min. Additionally, sulfasalazine inhibited cystine uptake in a concentration-dependent manner, presenting an IC50 value of 24.7 ± 5.6 μM. Cystine uptake was saturated with increasing concentration, demonstrating Km and Vmax values of 179.4 ± 26.7 μM and 30.4 ± 2.3 nmol/min/mg protein, respectively. Moreover, during cystine uptake with sulfasalazine, Km and Vmax were >300 μM and 8.0 ± 1.5 nmol/min/mg protein, respectively, suggesting that sulfasalazine might demonstrate a mixed inhibition pattern. Furthermore, xCT siRNA decreased the xCT mRNA level and reduced cystine uptake. In conclusion, xCT was involved in the cystine uptake in A549 cells and sulfasalazine showed a mixed inhibition pattern to xCT.

A549细胞半胱氨酸摄取及磺胺嘧啶抑制模式的动力学分析
胱氨酸/谷氨酸转运蛋白(xCT)是一种参与胱氨酸摄取和谷氨酸外排的反向转运蛋白。然而,关于xCT对癌细胞摄取胱氨酸的动力学分析,以及xCT抑制剂磺胺氮嗪对胱氨酸摄取的抑制模式的报道很少。因此,本研究的目的是阐明xCT在人肺癌细胞A549细胞中的动力学,并揭示磺胺氮嗪的抑制模式。胱氨酸摄取呈时间依赖性,在5分钟内呈线性摄取。此外,磺胺吡啶抑制胱氨酸摄取呈浓度依赖性,IC50值为24.7±5.6 μM。胱氨酸摄取随浓度的增加而趋于饱和,Km和Vmax分别为179.4±26.7 μM和30.4±2.3 nmol/min/mg蛋白。此外,在用磺胺氮嗪摄取胱氨酸时,Km和Vmax分别为>300 μM和8.0±1.5 nmol/min/mg蛋白,表明磺胺氮嗪可能表现出混合抑制模式。此外,xCT siRNA降低xCT mRNA水平,减少胱氨酸摄取。综上所述,xCT参与了A549细胞对胱氨酸的摄取,磺胺氮嗪对xCT表现出混合抑制模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
35
审稿时长
6-12 weeks
期刊介绍: Biopharmaceutics & Drug Dispositionpublishes original review articles, short communications, and reports in biopharmaceutics, drug disposition, pharmacokinetics and pharmacodynamics, especially those that have a direct relation to the drug discovery/development and the therapeutic use of drugs. These includes: - animal and human pharmacological studies that focus on therapeutic response. pharmacodynamics, and toxicity related to plasma and tissue concentrations of drugs and their metabolites, - in vitro and in vivo drug absorption, distribution, metabolism, transport, and excretion studies that facilitate investigations related to the use of drugs in man - studies on membrane transport and enzymes, including their regulation and the impact of pharmacogenomics on drug absorption and disposition, - simulation and modeling in drug discovery and development - theoretical treatises - includes themed issues and reviews and exclude manuscripts on - bioavailability studies reporting only on simple PK parameters such as Cmax, tmax and t1/2 without mechanistic interpretation - analytical methods
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信